<DOC>
	<DOCNO>NCT00251004</DOCNO>
	<brief_summary>The purpose study compare safety efficacy three immunosuppressive treatment regimen follow kidney transplant .</brief_summary>
	<brief_title>Efficacy Safety Study Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient race 18 70 year old ( inclusive ) Patients give write informed consent participate study Recipients multiorgan transplantation Recipients primary cadaveric primary nonhuman leucocyte antigen ( HLA ) identical living donor kidney transplantation . Graft cold ischemia time great 40 hour . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Renal transplantation , kidney , organ transplant</keyword>
	<keyword>Renal transplant rejection</keyword>
</DOC>